anti-transplant rejection (antiinflamtry) already in clin trials kills bc stem cells!

[Lani]

Blocking inflammation receptor kills breast cancer stem cells, study finds
[University of Michigan Health System]
ANN ARBOR, Mich. — Scientists at the University of Michigan Comprehensive Cancer Center have uncovered an important link between inflammation and breast cancer stem cells that suggests a new way to target cells that are resistant to current treatments.
The researchers identified a receptor, CXCR1, on the cancer stem cells which triggers growth of stem cells in response to inflammation and tissue damage. A drug originally developed to prevent organ transplant rejection blocks this receptor, killing breast cancer stem cells and preventing their metastasis in mice, according to the study.
Cancer stem cells, the small number of cells that fuel a tumor's growth, are believed to be resistant to current chemotherapies and radiation treatment, which researchers say may be the reason cancer so often returns after treatment. "Developing treatments to effectively target the cancer stem cell population is essential for improving outcomes. This work suggests a new strategy to target cancer stem cells that can be readily translated into the clinic," says senior study author Max S. Wicha, M.D., Distinguished Professor of Oncology and director of the U-M Comprehensive Cancer Center. Wicha was part of the team that first identified stem cells in breast cancer.
Results: of the current study appear online Jan. 4 in the Journal of Clinical Investigation and will appear in the journal's February print issue. CXCR1 is a receptor for Interleukin-8, or IL-8, a protein produced during chronic inflammation and tissue injury. When tumors are exposed to chemotherapy, the dying cells produce IL-8, which stimulates cancer stem cells to replicate. Addition of the drug repertaxin to chemotherapy specifically targets and kills breast cancer stem cells by blocking CXCR1.
Mice treated with repertaxin or the combination of repertaxin and chemotherapy had dramatically fewer cancer stem cells than those treated with chemotherapy alone. In addition, repertaxin-treated mice developed significantly fewer metastases than mice treated with chemotherapy alone. "These studies suggest that important links between inflammation, tissue damage and breast cancer may be mediated by cancer stem cells. Furthermore, anti-inflammatory drugs such as repertaxin may provide a means of blocking these interactions, thereby targeting breast cancer stem cells," Wicha says.
Repertaxin has been tested in early phase clinical trials to prevent rejection after organ transplantation. In these studies, side effects seem to be minimal. There are no reports of using repertaxin to treat cancer.
Note to patients: This work was done in cell cultures and mice. Repertaxin is not available to patients at this time and no clinical trials are yet planned.
Additional authors: Christophe Ginestier, Suling Liu, Mark Diebel, Hasan Korkaya, Ming Luo, Marty Brown, Jun-Lin Guan, Gabriela Dontu, all from U-M; and Julien Wicinski, Olivier Cabaud, Emmanuelle Charafe-Jauffret, Daniel Birnbaum, all from Universite de la Mediterranee, Marseille, France
Funding: National Institutes of Health, Breast Cancer Foundation, Taubman Institute, Department of Defense, Inserm, Institut Paoli-Calmettes, Institut National du Cancer, Ligue Nationale Contre le Cancer
Disclosure: The University of Michigan has filed for patent protection on this technology, and is currently looking for a commercialization partner to help bring the technology to market.
OPEN ACCESS: CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
[Journal of Clinical Investigation]
Recent evidence suggests that breast cancer and other solid tumors possess a rare population of cells capable of extensive self-renewal that contribute to metastasis and treatment resistance. We report here the development of a strategy to target these breast cancer stem cells (CSCs) through blockade of the IL-8 receptor CXCR1. CXCR1 blockade using either a CXCR1-specific blocking antibody or repertaxin, a small-molecule CXCR1 inhibitor, selectively depleted the CSC population in 2 human breast cancer cell lines in vitro. Furthermore, this was followed by the induction of massive apoptosis in the bulk tumor population via FASL/FAS signaling. The effects of CXCR1 blockade on CSC viability and on FASL production were mediated by the FAK/AKT/FOXO3A pathway. In addition, repertaxin was able to specifically target the CSC population in human breast cancer xenografts, retarding tumor growth and reducing metastasis. Our data therefore suggest that CXCR1 blockade may provide a novel means of targeting and eliminating breast CSCs.

[Rich66]

Large cancer stem cell therapy thread and available Repartaxin-like options HERE

[Laurel]

So fermented Soy, Nigella Satvia, and exercise...got it! Liked that patent site! BTW, been drinkin' that lousy green tea instead of my java. I hate you.......

[Ellie F]

Hi all
am losing the plot!
Are we saying that fermented soy (miso) and black cumin seed oil have some of these properties??
Ellie

[Laurel]

Ellie,

I was referencing the research Rich had posted previously (click on the HERE) in his post just above mine. I appreciate the information on using supplements and diet whenever possible to address some of these issues. Read through what Rich has posted and you will see a small link that will take you to the information regarding the soy and nigella.

The green tea reference, just so no one thinks I really hate Rich, is because he reminded me that in light of my ER+ status I should not be drinking coffee. I'm a Yank, darn it! I love the stuff. I have been trying to wean myself from the java jolt as I think Rich is probably totally correct, or at least I should heed the research however tentative. I am not a fan of green tea, so hence why I am disgruntled with dear Rich.

Yeah, I'm a brat....Funny thing, and please no one tell Rich, but I broke down and had a cup of joe when out shopping today because I felt sluggish and tired. Well, I honestly felt totally yukky after drinking it. Not guilty, but physically awful from it.